Research Centre: Dobney Hypertension Centre
Location: Level 3, Medical Research Foundation Building, Rear 50 Murray Street, Perth, WA 6000, Australia
Lead Researcher: Prof. Markus Schlaich MD, FAHA, FESC, ISHF
HREC: This study has been reviewed and approved by the University of Western Australia Institutional Review Board

About the Trial

High blood pressure, also known as hypertension, may increase the risk of heart attack and stroke. This is why managing high blood pressure is essential to prevent heart disease.

Researchers are continuously developing treatment options that may be effective and convenient for managing high blood pressure. This research trial seeks to determine the effectiveness of an investigational medication that combines three different blood pressure-lowering medications into a single tablet to be taken once a day. The 3 medications are: telmisartan, amlodipine and indapamide. All three of these medications are already prescribed in many countries to lower blood pressure and are used either independently or with each other in dual combinations.

Why Participate? 

• Participants will receive close monitoring and use of a blood pressure monitor during the trial at no cost. 
• Participants may experience improvements in their high blood pressure levels. 
• Participants will be contributing valuable information that may help others with high blood pressure.
• Participants will be helping to advance medical research.

Your Rights

• If you decide to participate in the trial and later feel that you no longer wish to be part of it, you can withdraw at any time.
• Any information that you provide will be kept strictly confidential, except as required by law.
• Qualified health professionals will monitor your health as it relates to the trial.

Who Can Participate?

• Men and women aged 18 years old or older who have high blood pressure.
• Must have mild to moderately high blood pressure.
• Must not have kidney disease, liver disease, or uncontrolled diabetes. Uncontrolled means that blood sugar levels are not within the ideal level despite using medication.
• Must not have had a history of cardiovascular disease e.g., unstable angina, heart attack, or stroke.
• Must not have tested positive for current COVID-19 infection or related illness.
• There are two studies that you could be a potential candidate for. For each, you must be able to attend 3-4 trial visits at the research site.  Each trial visit will take about 1-2 hours to complete. The study team can provide additional information about these visits.

Key Research Trial Details: 

• Participation in this trial would mean taking home blood pressure measurements using a blood pressure monitoring device provided by the research team.
• Participation will involve collecting blood and urine samples.

About the Research Centre:

 

Dobney Hypertension Centre
The Dobney Hypertension Centre (DHC) is a collaborative venture between The University of Western Australia and Royal Perth Hospital. It is led by Professor Markus Schlaich, an international leader in research of high blood pressure, otherwise known as hypertension.

DHC is accredited as a Hypertension Excellence Centre by the European Society of Hypertension, and engages in high quality clinical research with the ultimate aim to better understand the mechanisms that lead to elevated blood pressure. Throughout the year, numerous clinical trials and research studies are run by the dedicated research team that aim to both improve health outcomes, and optimize the treatment of hypertension across the community.

Please note:

Due to the current situation with the COVID-19 pandemic, the researchers would like to assure the participants that ensuring the safety of the participants as well as the research staff is of utmost importance.